ASCO GUIDELINES Bundle

Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475468

Contents of this Issue

Navigation

Page 3 of 71

4 Treatment Table A2: Immunosuppressive Agents Immunosuppressive Agents Dosing Indications Systemic Corticosteroids • Oral/IV prednisone 0.5–2 mg/kg/day • IV methylprednisolone 1–2 mg/kg/ day • Dexamethasone 10–20 mg IV In general, from Grade ≥2 irAE in any toxicity Topical Steroids Low strength • Hydrocortisone 1%, 2.5% (class 7) • Desonide 0.05% (class 6) Medium strength • Betamethasone valerate 0.1% (class 4) • Triamcinolone acetonide 0.1% (class 4) High strength • Fluocinonide 0.05% (class 2) Highest strength • Betamethasone dipropionate 0.05% (class 1) • Halobetasol 0.05% (class 1) Skin irAEs Biological immunosuppressive agents Abatacept (CTLA-4 agonist) 500 mg IV every 14 days × 5 doses Life-threatening and steroid-refractory myocarditis Alemtuzumab (Anti-CD52) 30 mg IV single dose Life-threatening and steroid-refractory myocarditis

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy